At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 44 enrolled
Drug / intervention
sildenafil citrate (UK-92,480)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-Center, Open-Label Study to Assess Safety and Efficacy of Sildenafil Citrate 20 mg TID in Subjects With Pulmonary Arterial Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Mar 30, 2007·Updated Feb 21, 2021
In Brief
A Phase 3 clinical trial evaluating sildenafil citrate (UK-92,480) for Pulmonary Hypertension. Completed, enrolled 44 participants across 8 sites.
Detailed Summary
To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartApr 2007
Primary CompletionFeb 2009
TodayJul 2026
First PostedMar 30, 2007
Enrollment StartApr 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.3 years ago
Interventions
sildenafil citrate (UK-92,480)drug
sildenafil citrate (UK-92,480)